Visual ImpairmentNCT06612190
Evaluation on Visual Outcome of TMS
A study testing TMS in people with Visual Impairment, run by Evidence Based Cataract Study Group at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients with visual impairment. The main question it aims to answer is: Does TMS improve the visual outcome in patients who suffer from visual impairment? Researchers will compare TMS to the… Read more about this study
- Who is it for?
- Ages 6 to 80 years
- Conditions the study is for
- Visual Impairment
- What is being tested?
- TMS
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 15 Sep 2024to Oct 2035
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Post cataract surgery or clear lens
- Best-corrected visual acuity less than 0.1logMAR
Who cannot join
- Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment;
- Diagnosed with ocular diseases that affect observation of visual function;
- History of epileptic seizures;
- Long term use of psychotropic drugs；
- Metal implants in the body.
Trial locations and contacts
1 site in 1 country.
China1 site
Eye and Ear, Nose Throat Hospital of Fudan University
Shanghai, Shanghai Municipality, 200031
About this study
Official title: Evaluation on Visual Outcome of Transcranial Magnetic Stimulation
The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients with visual impairment. The main question it aims to answer is:
- Does TMS improve the visual outcome in patients who suffer from visual impairment? Researchers will compare TMS to the control group who will not receive effective TMS treatment) to see if TMS works to improve the visual outcomes of the patients.
Participants will
- Undergo TMS treatment or no effective TMS for consecutive 5 days.
- Visit the clinic once every 2 weeks for checkups and tests.
- Conditions
- Visual Impairment
- Being tested
- TMS, Control
- Medical subject headings
- Vision Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TMSProcedure or surgery
TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
ControlProcedure or surgery
The control group will be given conventional consecutive care.
| Study group | Role | What they receive |
|---|---|---|
| TMS | Experimental | Not described Receives: Procedure: TMS |
| Control | Other | consecutive treatment Receives: Procedure: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual acuity
Measured: From enrollment to the end of treatment at 6 months
Secondary outcomes (1)
Visual field
Measured: From enrollment to the end of treatment at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2024
- Study start15 Sep 2024
- Primary completionOct 2030 (estimated)
- Study completionOct 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Visual ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Evidence Based Cataract Study Group
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, xiangjiazhu, Evidence Based Cataract Study Group
- Investigators
- Xiangjia Zhu, Study chair, Eye & ENT Hospital of Fudan UniversityYating Tang, Principal investigator, Eye & ENT Hospital of Fudan UniversityYinglei Zhang, Principal investigator, Eye & ENT Hospital of Fudan UniversityJiaqi Meng, Principal investigator, Eye & ENT Hospital of Fudan UniversityXin Liu, Principal investigator, Eye & ENT Hospital of Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06612190
- Sponsor's protocol ID
- EBCSG2024015
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2024
- Last updated
- 10 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation on Visual Outcome of Transcranial Magnetic Stimulation
- ClinicalTrials.gov ID
- NCT06612190
- Acronym / sponsor ID
- EBCSG2024015
- Conditions
- Visual Impairment
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Evidence Based Cataract Study GroupUniversity, hospital or other
- Study start
- 15 Sep 2024 (actual)
- Primary completion
- Oct 2030 (estimated)
- Study completion
- Oct 2035 (estimated)
- First posted
- 25 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients with visual impairment. The main question it aims to answer is:
- Does TMS improve the visual outcome in patients who suffer from visual impairment? Researchers will compare TMS to the control group who will not receive effective TMS treatment) to see if TMS works to improve the visual outcomes of the patients.
Participants will
- Undergo TMS treatment or no effective TMS for consecutive 5 days.
- Visit the clinic once every 2 weeks for checkups and tests.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TMS | Experimental | Procedure: TMS |
| Control | Other | Procedure: Controlconsecutive treatment |
Who may qualify
- Ages
- 6 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Post cataract surgery or clear lens
- Best-corrected visual acuity less than 0.1logMAR
Key exclusion criteria (5 listed)
- Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment;
- Diagnosed with ocular diseases that affect observation of visual function;
- History of epileptic seizures;
- Long term use of psychotropic drugs；
- Metal implants in the body.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TMSTMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days. | Procedure or surgery | TMS |
| ControlThe control group will be given conventional consecutive care. | Procedure or surgery | Control |
Primary outcome
Visual acuity
Time frame: From enrollment to the end of treatment at 6 months
1 secondary outcome
Visual field
Time frame: From enrollment to the end of treatment at 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
Related trials for Visual Impairment
Active, not recruitingPhase 4
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Geographic Atrophy, Age-Related Macular Degeneration
Not yet recruiting
Multisensory Rehabilitation of Vision Loss After Cortical Damage
Cortical Blindness
Not yet recruiting
Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
Macular Degeneration, Central Visual Impairment
RecruitingPhase 1
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Stargardt Disease, Stargardt Macular Dystrophy
Not yet recruiting
joyVision: The Superiority of Co-design in the Development of a Serious Game for Children With Cerebral Visual Impairment
Cerebral Visual Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiangjia Zhu study chair
Eye & ENT Hospital of Fudan University
Yating Tang principal investigator
Eye & ENT Hospital of Fudan University
Yinglei Zhang principal investigator
Eye & ENT Hospital of Fudan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TMS in people with Visual Impairment, run by Evidence Based Cataract Study Group at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual acuity (time frame: From enrollment to the end of treatment at 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.